

104. (NEW) The method of any one of claims 92-100, wherein said CD28 or CTLA4 ligand is B7-1 and B7-2.

105. (NEW) The method of claim 101, wherein said CD28 or CTLA4 ligand is B7-1.

A2 106. (NEW) The method of claim 101, wherein said CD28 or CTLA4 ligand is B7-2.

107. (NEW) The method of claim 101, wherein said CD28 or CTLA4 ligand is B7-1 and B7-2.

REMARKS

Claim 1 has been canceled. The cancellation of this claims should in no way be construed as an acquiescence by Applicants to any of the rejections of record involving this claim.

Claims 92-107 have been newly added. Support for the new claims can be found throughout the specification including the claims as originally filed.


No new matter has been added.

Any amendments to and/or cancellation of the claims should in no way be construed as an acquiescence to any of the Examiner's rejections and was done solely to expedite prosecution. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

CONCLUSION

It is respectfully submitted that this application is in condition for allowance. If a telephone conversation with Applicants' attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' attorney at (617) 227-7400.

Respectfully submitted,



DeAnn F. Smith, Esq.
Registration No. 36,683
Attorney for Applicants

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
Tel. (617) 227-7400

Dated: November 28, 2001

NOV 29 2001